menu search

Futura medical wins new product award from boots

Futura Medical's Eroxon erectile dysfunction treatment won the "New Product of the Year, Healthcare" c...

November 2, 2023, 12:15 pm

Kura oncology and mirati therapeutics enter into clinical collaboration and supply agreement to evaluate ko-2806 and adagrasib in krasᴳ¹²ᶜ-mutated nsclc

– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 – SAN DIE...

November 2, 2023, 11:30 am

Autolus therapeutics reports third quarter 2023 financial results and business updates

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymp...

November 2, 2023, 11:11 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Immunic gets notice of allowance for us patent protecting treatment of relapsing ms with vidofludimus and salts

Immunic Inc (NASDAQ:IMUX) told investors it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application protec...

November 2, 2023, 8:13 am

Regeneron beats quarterly profit estimates on eczema treatment strength

Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema tre...

November 2, 2023, 6:42 am

Molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...

November 2, 2023, 2:00 am

Tarsus to report third quarter 2023 financial results on thursday, november 9, 2023

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply pro...

November 1, 2023, 10:35 pm

Biocardia to host q3 2023 corporate update and financial results conference call on november 8, 2023

SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the t...

November 1, 2023, 9:04 pm

Tarsus to report third quarter 2023 financial results on thursday, november 9, 2023

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply prov...

November 1, 2023, 6:35 pm

Biocardia to host q3 2023 corporate update and financial results conference call on november 8, 2023

SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the tr...

November 1, 2023, 5:04 pm

Gracell biotechnologies to participate in four upcoming investor conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDA...

November 1, 2023, 4:00 pm

Tourmaline bio: ted and ascvd targeting with differentiated il-6

Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye dise...

November 1, 2023, 2:09 pm

Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting

– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared ...

November 1, 2023, 10:30 am

Tearsolutions, inc. appoints robert dempsey to its board of directors

Dempsey brings worldwide Ophthalmology leadership experience in driving successful drug development CHARLOTTESVILLE, Va., Nov. 01, 2023 (GLOBE NEWSWIR...

November 1, 2023, 10:00 am

Scancell melanoma trial data chosen for poster presentation at sitc

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that it has been selected for a poster presentation of data from the first stage of its Pha...

November 1, 2023, 4:16 am

Astrazeneca inks gene editing deal that could end up costing it $2.5bn

AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) ...

November 1, 2023, 3:59 am

Gsk raises outlook amid strong demand for new rsv vaccine

GSK PLC (LSE:GSK, NYSE:GSK) said a strong third quarter performance has driven a further upgrade to full-year guidance boosted by demand for its respi...

November 1, 2023, 3:31 am

Apnimed announces launch of joint venture with shionogi to develop novel pharmacologic therapies for obstructive sleep apnea and other sleep disorders

$150M transaction supporting early and clinical-stage pipeline development in OSA and related sleep disorders to find oral pharmacologic solutions for...

November 1, 2023, 12:00 am


Search within

Pages Search Results: